Since IL-6 blockade has positive effects on glycosylated hemoglobin levels compared with TNF inhibition, and since it also decreases NT-proBNP levels, increases the left ventricular ejection fraction, and decreases the left ventricular mass index in patients with RA [37–40], it is conceivable that the overall comorbidity status of patients may not be affected by ADA, whereas IL-6 blockade by OKZ may improve it. The gene discussed is IL6; the disease is rheumatoid arthritis.